Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection
SARS-CoV-2, a member of the coronavirus family, is the causative agent of the COVID-19 pandemic. Currently, there is still an urgent need in developing an efficient therapeutic intervention. In this study, we aimed at evaluating the therapeutic effect of a single intranasal treatment of the TLR3/MDA5 synthetic agonist Poly(I:C) against a lethal dose of SARS-CoV-2 in K18-hACE2 transgenic mice. We demonstrate here that early Poly(I:C) treatment acts synergistically with SARS-CoV-2 to induce an intense, immediate and transient upregulation of innate immunity-related genes in lungs. This effect is accompanied by viral load reduction, lung and brain cytokine storms prevention and increased levels of macrophages and NK cells, resulting in 83% mice survival, concomitantly with long-term immunization. Thus, priming the lung innate immunity by Poly(I:C) or alike may provide an immediate, efficient and safe protective measure against SARS-CoV-2 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Viruses - 14(2022), 2 vom: 19. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tamir, Hadas [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.03.2022 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/v14020189 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337472904 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337472904 | ||
| 003 | DE-627 | ||
| 005 | 20231225234502.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/v14020189 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1124.xml |
| 035 | |a (DE-627)NLM337472904 | ||
| 035 | |a (NLM)35215785 | ||
| 035 | |a (PII)189 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tamir, Hadas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.03.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a SARS-CoV-2, a member of the coronavirus family, is the causative agent of the COVID-19 pandemic. Currently, there is still an urgent need in developing an efficient therapeutic intervention. In this study, we aimed at evaluating the therapeutic effect of a single intranasal treatment of the TLR3/MDA5 synthetic agonist Poly(I:C) against a lethal dose of SARS-CoV-2 in K18-hACE2 transgenic mice. We demonstrate here that early Poly(I:C) treatment acts synergistically with SARS-CoV-2 to induce an intense, immediate and transient upregulation of innate immunity-related genes in lungs. This effect is accompanied by viral load reduction, lung and brain cytokine storms prevention and increased levels of macrophages and NK cells, resulting in 83% mice survival, concomitantly with long-term immunization. Thus, priming the lung innate immunity by Poly(I:C) or alike may provide an immediate, efficient and safe protective measure against SARS-CoV-2 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Poly(I:C) | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a TLR3 | |
| 650 | 4 | |a hACE2-K18 transgenic mice | |
| 650 | 4 | |a innate immune response | |
| 650 | 7 | |a Toll-Like Receptor 3 |2 NLM | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Poly I-C |2 NLM | |
| 650 | 7 | |a O84C90HH2L |2 NLM | |
| 700 | 1 | |a Melamed, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Erez, Noam |e verfasserin |4 aut | |
| 700 | 1 | |a Politi, Boaz |e verfasserin |4 aut | |
| 700 | 1 | |a Yahalom-Ronen, Yfat |e verfasserin |4 aut | |
| 700 | 1 | |a Achdout, Hagit |e verfasserin |4 aut | |
| 700 | 1 | |a Lazar, Shlomi |e verfasserin |4 aut | |
| 700 | 1 | |a Gutman, Hila |e verfasserin |4 aut | |
| 700 | 1 | |a Avraham, Roy |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Shay |e verfasserin |4 aut | |
| 700 | 1 | |a Paran, Nir |e verfasserin |4 aut | |
| 700 | 1 | |a Israely, Tomer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Viruses |d 2009 |g 14(2022), 2 vom: 19. Jan. |w (DE-627)NLM192382764 |x 1999-4915 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:2 |g day:19 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/v14020189 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 2 |b 19 |c 01 | ||